LA-based probiotic company Seed is launching a new vaginal suppository that will help women maintain a more stable vaginal microbiome.

An optimal vaginal microbiome is a key driver of gynecological, urogenital, and reproductive healthVS-01™ is a multi-strain probiotic and prebiotic clinically validated to establish an optimal vaginal microbiome and sustain regulated vaginal pHBuilt on the research of renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01™ is the first to pioneer a microbial genomics approach powered by the most comprehensive host-microbiome vaginal data setLOS ANGELES, May 21, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today launched VS-01™ Vaginal Synbiotic, the first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome dominated by Lactobacillus crispatus, the vagina's most protective bacteria. Dr. Jacques Ravel's pioneering research has elucidated the crucial role of the vaginal microbiome in gynecological, urogenital, and reproductive health, though everyday factors like stress, sex, menstruation, and diet can disrupt its equilibrium and deplete the abundance of L. crispatus. Dr

The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01®BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations."DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics," stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal."Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, "The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics."DDW Presentation Highlights"Effects of a multi-species synbiotic on microbiome resilience and gastrointestinal barrier function after antibiotics: A randomized, double-blind, placebo-controlled clinical trial."This clinical trial evaluated the effects of DS-01® on individuals during and after antibiotic usage. Key findings include: DS-01® significantly improved short-term (25% at Day 7) and long-term (49% by Day 91) gut barrier integrity during and following broad-spectrum antibiotics